Christopher Bloomstran’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Christopher Bloomstran’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-117	Closed	-$112K	–	30
2016 Q3	$112K	Sell	117 -1	-0.8%	-$1.26K	0.08%	30
2016 Q2	$168K	Hold	118	–	–	0.12%	30
2016 Q1	$145K	Sell	118 -1	-0.8%	-$1.15K	0.1%	30
2015 Q4	$153K	Sell	119 -9	-7%	-$11.7K	0.11%	32
2015 Q3	$185K	Sell	128 -1	-0.8%	-$1.93K	0.13%	31
2015 Q2	$284K	Hold	129	–	–	0.19%	30
2015 Q1	$384K	Hold	129	–	–	0.25%	29
2014 Q4	$427K	Hold	129	–	–	0.27%	27
2014 Q3	$456K	Sell	129 -1	-0.8%	-$3.89K	0.28%	27
2014 Q2	$498K	Hold	130	–	–	0.29%	26
2014 Q1	$527K	Hold	130	–	–	0.3%	26
2013 Q4	$482K	Hold	130	–	–	0.27%	29
2013 Q3	$511K	Hold	130	–	–	0.3%	28
2013 Q2	$1.28M	Buy	+130	New	+$1.44M	0.75%	24

Other funds holding FRTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Christopher Bloomstran's FRTX Position: Q4 2016 in Review

Christopher Bloomstran sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2016, closing a stake of 117 shares — an estimated $112K sold.

Christopher Bloomstran first reported a position in FRTX in Q2 2013 and held it in 14 quarters. The position peaked at $1.28M in Q2 2013. 26 funds tracked by Wall St. Rank hold FRTX as of Q4 2016.

Christopher Bloomstran reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Christopher Bloomstran sold 117 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $112K.
Christopher Bloomstran first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 14 quarters.
Christopher Bloomstran's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1.28M in Q2 2013.
26 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Semper Augustus Investments Group's 13F filing for Q4 2016, filed 13 Feb 2017.